A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD): Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) (NCT06190093), a na phase 3 study. The primary outcome is Evaluate the Effectiveness of Intravitreal Injections of ONS-5010 Compared to Ranibizumab in Preventing Vision Loss, as Measured by the Mean Change in Baseline Best Correct Visual Acuity (BCVA) at Week 8.

2. Clinical Question

3. Trial Design

NORSE EIGHT is listed as a Phase 3, parallel study with triple masking. Its title describes a 3-month study, and the registry lists 400 participants enrolled. The record gives a start date of 2024-01-24, a primary completion date of 2024-11-07, and a completed status. It describes the study as multicenter, randomized, masked, and controlled.

There is an important qualification to the randomized-comparison interpretation. Although the brief summary calls the study randomized, allocation is coded as NA, and the registry explicitly cautions that this is not a randomized comparison and that the arms are not a like-for-like control comparison. The record does not explain this coding or describe the allocation process. Therefore, the presence of two named arms does not by itself establish that their outcomes can be interpreted as a randomized treatment contrast.

The listed biological interventions are bevacizumab and ranibizumab. The arm descriptions are blank, so treatment details beyond those names and the stated intravitreal administration of ONS-5010 are not reported in the registry record. The record identifies a primary endpoint at week 8, while the study title describes a 3-month duration. It does not explain the relationship between that endpoint timeframe and the overall study duration.

The registry lists one outcome measure and no analyses. A statistical analysis plan, analysis populations, participant flow, and details of masking implementation are not reported in the registry record. Those omissions limit how fully the design and its intended comparison can be assessed from the record alone.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Evaluate the Effectiveness of Intravitreal Injections of ONS-5010 Compared to Ranibizumab in Preventing Vision Loss, as Measured by the Mean Change in Baseline Best Correct Visual Acuity (BCVA) at Week 8, measured over Baseline, 8 weeks.

The primary endpoint is mean change in best corrected visual acuity from baseline to week 8, measured in letters read on Early Treatment Diabetic Retinopathy Study charts. The registry states that a positive change represents an improvement in visual acuity. The stated purpose is to evaluate whether intravitreal injections of ONS-5010 prevent vision loss compared with ranibizumab.

As a continuous measure, visual-acuity change retains information about the size and direction of changes rather than reducing participants to categories such as improved or not improved. The group mean describes average change, while the standard deviation describes how much individual changes vary around that mean. These answer different questions: an average can summarize the group while still concealing substantial variation among participants.

The endpoint description identifies the measurement instrument and timepoint, but does not report the mean change in either arm, a between-arm estimate, uncertainty around an estimate, or a statistical test. Those results are not reported in the registry record. Consequently, the endpoint definition can be explained, but the treatment contrast cannot be evaluated from the posted primary-outcome information.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry describes a continuous primary outcome: mean change in visual acuity measured in ETDRS letters from baseline to week 8. The record gives the mean as the summary parameter and standard deviation as the measure of dispersion. It does not report the actual outcome values, a treatment contrast, or an inferential analysis. The concepts below are general explanations of how such analyses are commonly interpreted; they do not describe an analysis confirmed for this trial.

What does a mean change describe?

A change score represents the difference between a participant’s follow-up measurement and baseline measurement. The mean change summarizes those participant-level changes within a group. Because the endpoint description says that a positive change represents improvement, the sign of a reported mean would have a direct directional interpretation. A group mean is not the experience of every participant: some individual changes can differ from the average, and the mean alone does not show the distribution of outcomes.

What does the standard deviation add?

In general, the standard deviation describes the spread of participant values around the group mean. It is not the same as the uncertainty around the mean or around a difference between groups. A larger spread indicates that individual outcomes are more variable; a smaller spread indicates that values are more concentrated around the mean. The registry identifies standard deviation as the dispersion measure but does not report its value for the primary endpoint.

How would a comparison be interpreted?

For a comparison of mean changes, the estimated contrast would describe how far apart the group averages are on the letter scale, with direction depending on the order used for the subtraction. A confidence interval around that contrast would express statistical uncertainty and precision. A narrower interval generally indicates greater precision under the model, while a wider interval indicates greater uncertainty. Statistical significance, if reported, would address compatibility with a specified null model; it would not on its own describe the size or practical importance of a difference. No confidence interval, test statistic, or p-value for the primary outcome is reported in the registry record.

Why does the comparison design matter?

General statistical interpretation of a treatment contrast depends on the design that generated the groups. Random allocation can, when implemented and maintained appropriately, support comparisons by reducing systematic differences between groups. Here, the brief summary describes the study as randomized, but allocation is coded NA and the record warns that the arms are not a like-for-like control comparison. The registry does not explain the discrepancy, so a reader cannot determine from this record alone what allocation method was used or how the warning should affect interpretation.

Masking is listed as triple, but the record does not identify which parties were masked or describe how masking was implemented. Parallel model is listed, which identifies the stated model structure, but further operational details are not reported in the registry record. These labels give design context without replacing information about conduct, adherence, or analysis.

What do planning calculations mean?

General sample-size planning asks how many participants may be needed to detect a specified effect under stated assumptions. The registry describes planning illustrations based on an observed effect, a two-sided significance level of 0.05, equal allocation, a normal approximation, and an effect defined as a stated fraction of that observed effect. Such calculations are planning illustrations, not observed trial results and not observed power. The record does not report the numerical illustration outputs in the registry record described for this analysis, and the calculations are not the trial’s own design justification. A sample-size rationale for the trial is not reported in the registry record.

In general, assumptions about the target effect, outcome variability, significance level, allocation, and analysis method can all affect a planning result. A planning illustration cannot show that the trial actually achieved a particular degree of precision, and it cannot substitute for the observed estimate and its uncertainty. The registry’s caution about comparability is also relevant: a planning calculation does not remedy limitations in the design or make two groups exchangeable.

What is not established by the registry?

The record lists no analyses. It does not report a statistical model, covariate adjustment, handling of baseline values, missing-data procedure, analysis population, multiplicity strategy, or interim analysis. It is therefore not possible to determine whether the primary endpoint was analyzed as a change score, with baseline adjustment, or by another method. These are general methodological considerations, not claims about procedures used in this study. The absence of a description should be read as information not reported in the registry record, rather than evidence that a particular procedure was or was not performed.

10. Confidence Intervals for Each Arm

No two-arm comparison is shown for this trial, but each arm's mean can be given with a t-based 95% confidence interval computed from the posted mean, spread and number of participants.

R code and output

arm <- c("ONS-5010 Bevacizumab", "Ranibizumab")
n   <- c(197, 198)
m   <- c(63, 66.2)
sp  <- c(13.5, 12.6)
sd  <- sp      # posted standard deviations
for (i in seq_along(n)) {
  se <- sd[i] / sqrt(n[i]); h <- qt(0.975, n[i] - 1) * se
  cat(sprintf("CARM|%s|%d|%.3f|%.3f|%.3f|%.3f\n", arm[i], n[i], m[i], sd[i], m[i] - h, m[i] + h))
}

CARM  ONS-5010 Bevacizumab  197  63.000  13.500  61.103  64.897
CARM  Ranibizumab  198  66.200  12.600  64.434  67.966

11. Multiplicity, Missing Data and Analysis Populations

The registry identifies one outcome measure and no analyses. It does not report a multiplicity strategy or explain whether other outcomes, timepoints, or subgroup comparisons were considered in the analysis. In general, testing multiple outcomes or comparisons can increase the chance of a false-positive finding if no suitable approach is used. Whether that concern applies, and how it might have been addressed, is not reported in the registry record.

Missing outcome data can affect a mean-change analysis because participants without a week 8 measurement may differ from those with observed measurements. General approaches to missing data make assumptions about those unobserved outcomes; conclusions can depend on whether those assumptions are plausible. The registry does not report the amount or pattern of missing primary-endpoint data, the reasons for missingness, or the method used to handle it.

The analysis population is also not reported in the registry record. It is not possible to determine whether the analysis included all enrolled participants, only participants with endpoint measurements, or another defined group. The record does not describe protocol deviations, treatment discontinuation, adherence, or how such events were handled in the primary analysis.

These gaps do not establish that the study failed to address multiplicity or missing data. They mean that the registry record does not provide the details needed to assess those choices or their possible effect on the primary result. The same caution applies to interim analyses and the full statistical plan, neither of which is reported in the registry record.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: acute coronary syndrome (0.5%), coronary artery disease (0.5%), myocardial infarction (0.5%), iridocyclitis (0.5%), dysphagia (0.5%).

The registry lists serious adverse events for 9 of 200 participants at risk in the ONS-5010 Bevacizumab group and 5 of 200 in the Ranibizumab group. It lists other adverse events for 24 of 200 and 5 of 200, respectively, and deaths of 0 in each group. These figures are counts with the stated numbers at risk; they are not a comparison adjusted for design or participant characteristics.

The serious-event terms listed at 0.5% each are acute coronary syndrome, coronary artery disease, myocardial infarction, iridocyclitis, dysphagia, and intestinal obstruction. The record does not clarify whether terms may overlap within participants, or provide details such as event timing, duration, severity criteria, or relationship to treatment. The term list should therefore be read as registry-reported event information, not as a complete clinical description.

In general, adverse-event counts describe what was recorded in the specified groups. A causal safety comparison requires context about how events were collected, how long participants were followed, and how the groups were formed. Those details are not reported in the registry record, and the record itself cautions against treating the arms as a like-for-like control comparison. The counts do not establish why an event occurred.

13. What the Result Does, and Does Not, Mean

The record establishes that NORSE EIGHT was registered as a Phase 3 study of ONS-5010, identified as bevacizumab, compared with ranibizumab in subjects with neovascular age-related macular degeneration. It defines a primary visual-acuity measure, mean change from baseline to week 8 in ETDRS letters, and indicates that positive change represents improvement. It also reports selected adverse-event counts and a completed study status.

What the record does not establish is the numerical primary-endpoint result. There is no reported group mean change, between-group estimate, confidence interval, or p-value, and no analyses are listed. The absence of these results cannot be interpreted as evidence that the treatments had the same outcomes, nor as evidence that either group had a better outcome. The direction and precision of the primary comparison remain unknown from the registry record.

Interpretation also requires attention to the design note. The brief summary describes a randomized study, but allocation is coded as NA and the registry says the arms are not a like-for-like control comparison. Without further explanation, the record does not support treating the arm contrast as an unqualified randomized comparison.

The safety counts describe events recorded in each group, but do not by themselves show that an intervention caused or prevented an event. Definitions, timing, data collection methods, and a statistical safety comparison are not reported in the registry record. The counts are therefore descriptive rather than a complete basis for comparative safety conclusions.

In general, an endpoint definition, a design description, and observed estimates answer different questions. The endpoint tells what was intended to be measured; the design informs how a comparison might be interpreted; numerical results and uncertainty show what the observed data indicate. The registry record contains the first elements and selected safety counts, but not enough primary-outcome analysis to assess comparative effectiveness.

14. Why This Trial Matters Statistically

Statistically, this record illustrates why a clearly named endpoint is not the same as an interpretable result. The primary measure is specified as mean change in visual acuity, with a defined scale, timeframe, and direction. Those details help readers understand what an eventual estimate would represent. But without the group estimates and uncertainty, the central comparative question cannot be answered from the registry record.

The record also highlights the importance of reconciling design descriptions. Randomization is stated in the brief summary, yet allocation is coded as NA and the registry warns that the arms are not a like-for-like control comparison. That qualification affects how a reader should approach any apparent difference between groups. Further design details are not reported in the registry record.

For clinical researchers and biostatisticians, the distinction between outcome definition, analysis, and interpretation is fundamental. A mean describes an average; a standard deviation describes spread; an interval describes uncertainty in an estimate. Those quantities are not interchangeable, and none is present for the primary outcome in this record. The listed adverse-event counts provide a separate, descriptive view of safety reporting, not a substitute for the visual-acuity analysis.

The record is therefore useful for identifying the study question and some design and safety information, while also showing the limits of conclusions that can be drawn when primary results and analysis details are absent. In general, transparent reporting of estimates, uncertainty, analysis populations, and missing-data handling is what allows readers to evaluate both the result and its reliability.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main trial-specific limitation in the registry record is the absence of numerical primary-endpoint results. Although the endpoint and timeframe are specified, the record does not report mean changes, a between-arm estimate, uncertainty, or a statistical test. It also lists no analyses, so the method used to produce a primary comparison cannot be assessed.

The design information is qualified by an unresolved inconsistency: the brief summary calls the study randomized, while allocation is coded as NA and the registry cautions that the arms are not a like-for-like control comparison. The record does not explain the allocation coding or describe the process that produced the groups. This makes it difficult to assess whether and how the groups support a causal comparison.

The title describes a 3-month study, while the primary endpoint is specified at week 8. The registry does not explain the relationship between the overall study duration and this endpoint timeframe. It also does not provide details of treatment schedules, participant characteristics, follow-up completeness, or endpoint missingness.

The safety information is limited to counts and listed serious-event terms. Event definitions, collection methods, follow-up time, participant-level overlap, and statistical comparisons are not reported in the registry record. The analysis population, multiplicity approach, missing-data method, and statistical analysis plan are also not reported. These limitations restrict interpretation of both the primary question and the safety counts; they do not establish that unreported methods or results do not exist outside the registry record.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) — NCT06190093.
• Registry record last updated 2026-07-23; status last verified 2026-07.
• Results first posted 2026-06-30.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

NCT06190093 is the registry record for NORSE EIGHT, a completed Phase 3 study of ONS-5010, identified as bevacizumab, compared with ranibizumab in neovascular age-related macular degeneration. It lists 400 enrolled participants, a parallel model, and triple masking. The stated primary endpoint is mean change in ETDRS visual-acuity letters from baseline to week 8, with positive change indicating improvement.

The record reports serious adverse events in 9 of 200 participants at risk in the ONS-5010 Bevacizumab group and 5 of 200 in the Ranibizumab group. Other adverse events affected 24 of 200 and 5 of 200, respectively; deaths are listed as 0 in each group. The record lists no analyses and does not report a numerical primary-endpoint result. It also cautions that the arms are not a like-for-like control comparison.